These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37591705)

  • 21. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
    Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
    Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pertactin-deficient
    Barkoff AM; Mertsola J; Pierard D; Dalby T; Hoegh SV; Guillot S; Stefanelli P; van Gent M; Berbers G; Vestrheim D; Greve-Isdahl M; Wehlin L; Ljungman M; Fry NK; Markey K; He Q
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy - a prospective, observational cohort study from the United Kingdom.
    Rice TF; Diavatopoulos DA; Smits GP; van Gageldonk PGM; Berbers GAM; van der Klis FR; Vamvakas G; Donaldson B; Bouqueau M; Holder B; Kampmann B
    Clin Exp Immunol; 2019 Jul; 197(1):1-10. PubMed ID: 30758857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The property of filamentous hemagglutinin of Bordetella pertussis].
    Chow MP; Lin CK; Lin JS; Chau WK; Ho CH; Chen SY; Lee SH; Yung CH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Nov; 24(4):331-8. PubMed ID: 1845342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acellular pertussis vaccines and the role of pertactin and fimbriae.
    Poolman JT; Hallander HO
    Expert Rev Vaccines; 2007 Feb; 6(1):47-56. PubMed ID: 17280478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
    Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
    Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
    Cherry JD; Heininger U; Richards DM; Storsaeter J; Gustafsson L; Ljungman M; Hallander HO
    Clin Vaccine Immunol; 2010 May; 17(5):741-7. PubMed ID: 20335431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of
    Bouchez V; Guillot S; Landier A; Armatys N; Matczak S; ; Toubiana J; Brisse S
    Euro Surveill; 2021 Sep; 26(37):. PubMed ID: 34533118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry.
    Long Z; Wei C; Zhan Z; Ma X; Li X; Li Y; Yao J; Ji F; Li C; Huang T
    J Pharm Biomed Anal; 2019 May; 169():30-40. PubMed ID: 30831450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
    Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
    Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses.
    Zimmermann P; Perrett KP; Messina NL; Donath S; Ritz N; van der Klis FRM; Curtis N
    EClinicalMedicine; 2019 Aug; 13():21-30. PubMed ID: 31517260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of Bordetella pertussis strains which do not produce virulence factors in the epidemiology of pertussis.
    Polak M; Lutyńska A
    Postepy Hig Med Dosw (Online); 2017 May; 71(0):367-379. PubMed ID: 28513461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hydromechanical forces on the production of filamentous haemagglutinin and pertussis toxin of Bordetella pertussis.
    Rodríguez ME; Samo AL; Hozbor DF; Yantorno OM
    J Ind Microbiol; 1993 Feb; 12(2):103-8. PubMed ID: 7764157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elimination of light chain tailing in reducing capillary electrophoresis with sodium dodecyl sulfate analysis of a monoclonal antibody.
    Wang ST; Gao H; Shen BB; Wang H; Fang WJ
    Electrophoresis; 2022 Oct; 43(18-19):1850-1858. PubMed ID: 35776503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
    Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
    Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The purification and characterization of an acellular pertussis vaccine.
    Chazono M; Yoshida I; Konobe T; Fukai K
    J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.
    Isacson J; Trollfors B; Hedvall G; Taranger J; Zackrisson G
    Scand J Infect Dis; 1995; 27(3):273-7. PubMed ID: 8539553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.